PubMed Health⌕ Search

Biomedical subjects

R Afar

Publications and source records attributed to R Afar.

13 recordsLinked to original sources
PubMed1996

Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decarboxylase gene is regulated by hepatocyte nuclear factor 1.

The rat aromatic l-amino acid decarboxylase (AADC) gene contains alternative promoters which direct expression of neuronal and nonneuronal mRNAs that differ only in their 5'-untranslated regions (UTRs). We have analyzed the expression of the nonneuronal promoter of the rat AADC gene in the kidney epithelial cell line LLC-PK1 and in cells which do not express the nonneuronal form of AADC by transient transfection. These studies revealed that the first 1.1 kilobases of the nonneuronal promoter, including the nonneuronal-specific 5'-UTR (Exon 1), contains sufficient information to direct tissue-specific expression. Serial deletions of this promoter localized the cis-active element to a region between -52 and -28 base pairs upstream of the nonneuronal transcription start site. An A/T-rich sequence, within this region which we have termed KL-1, was found to bind a kidney and liver-specific factor by DNase footprint analysis and was capable of directing tissue-specific expression from a heterologous promoter. Moreover, when the KL-1 sequence was mutated in the context of the entire promoter sequence, all transcriptional activity was abolished. DNA sequence comparison revealed that the KL-1 fragment is highly homologous to the binding site for hepatocyte nuclear factor-1 (HNF-1). Mobility shift studies utilizing an antibody to HNF-1 demonstrated binding of HNF-1 to the KL-1 fragment and cotransfection of HNF-1 cDNA into cells which do not express the nonneuronal form of AADC resulted in activation of transfected AADC nonneuronal promoter constructs. These results strongly suggest that the transcription factor which regulates the tissue-specific expression of the nonneuronal form of AADC mRNA is HNF-1.

Animals↗
PubMed1996

Positive and negative elements contribute to the cell-specific expression of the rat dopamine beta-hydroxylase gene.

Dopamine beta-hydroxylase catalyzes the final step in noradrenaline synthesis and is expressed exclusively in noradrenergic and adrenergic cells. In order to identify elements within the dopamine beta-hydroxylase (DBH) gene which contribute to the regulation of tissue-specific expression, we have analyzed the expression of the rat DBH promoter by transient transfection in both DBH-expressing and non-expressing cell lines. We have found that 1 kilobase of the DBH promoter can direct expression of the luciferase reporter gene in the DBH-expressing PC12, CATH.a, and SK-N-SH cell lines, but not in the non-DBH-expressing C6 glioma or CA77 cell lines. This activity was localized to a region between -133 and -173 upstream of the transcription start site. This element, however, also directed expression in non-DBH-expressing cell lines, but was inhibited when sequences between -212 and -388 were included. This inhibitory region contains sequences homologous to a silencer element recently identified in the human DBH gene, and shares homology with other previously identified silencer elements. Gel retardation experiments demonstrate that the rat DBH inhibitory region and the silencer elements found in the rat sodium type II channel and SCG10 genes bind a similar factor. The region between -133 and -173, which contains a consensus cyclic AMP response element (CRE), was also found to be responsive to cAMP in both DBH-expressing and non-expressing cells. Inclusion of sequences between -173 and -190 diminished the cAMP induction in PC12 cells, and nearly abolished the induction in C6 and CA77 cells, suggesting the presence of an additional negative element which inhibits cAMP induction in non-DBH expressing cells. DNA binding assays using antibodies to CRE binding protein-related transcription factors identified ATF-1 binding to the rat DBH-CRE, and further suggest that inhibition of cAMP regulation may be due to inhibition of ATF-1 binding by an additional factor, which binds to the DBH promoter immediately upstream of the CRE. These results demonstrate the importance of both positive and negative regulatory elements in the regulation of tissue-specific expression of the rat DBH gene.

Analysis of Variance↗
PubMed1994

Nicotine-induced intracellular calcium changes are not antagonized by alpha-bungarotoxin in adrenal medullary cells.

The snake toxin alpha-bungarotoxin distinguishes between neuronal nicotinic receptor subtypes. In chick ciliary ganglion neurons, activation of alpha-bungarotoxin-sensitive nicotinic receptors has been proposed to produce elevations in intracellular calcium levels. In the present study we show that prolonged treatment with alpha-bungarotoxin did not affect the nicotine-evoked calcium response in suspended chromaffin cells. On the other hand, the classical nicotinic receptor blocker d-tubocurarine potently blocked nicotinic receptor mediated effects. The degree of inhibition of the nicotinic response observed with d-tubocurarine was not modified by prior treatment with alpha-bungarotoxin. These results suggest that nicotinic alpha-bungarotoxin receptors are not primarily involved in nicotine-mediated increases in intracellular calcium in bovine adrenal medullary cells.

Adrenal Medulla↗
PubMed1993

Modulation of nicotinic acetylcholine receptor function in bovine adrenal chromaffin cells by thymopentin.

Thymopentin is a five amino acid peptide which corresponds to amino acids 32-36 of the thymic polypeptide thymopoietin. Previous work had shown that TP-5 could modulate responsiveness at the muscle-type nicotinic receptor. The present studies show that neuronal nicotinic receptor function, measured as radiolabelled noradrenaline release from bovine adrenal medullary cells, was attenuated by thymopentin. The pentapeptide exhibited specificity for nicotinic receptor evoked release, since thymopentin did not affect potassium-stimulated secretion of [3H]noradrenaline. It appears, therefore, that thymopentin antagonizes catecholamine release by specifically modulating nicotinic receptor responsiveness.

Acetylcholine↗
PubMed1993

Retraction notice.

Explore the source record for details and available documents.

Retraction Notice↗
PubMed1992

Thymopoietin, a polypeptide ligand for the alpha-bungarotoxin binding site in brain: an autoradiographic study.

Thymopoietin, a 48-49-amino acid polypeptide present in the thymus gland, was investigated as a potential ligand for the neuronal nicotinic alpha-bungarotoxin binding site in rat brain. Binding of [125I]alpha-bungarotoxin to whole rat brain sections was inhibited by thymopoietin in a concentration-dependent manner with an IC50 of 30.0 +/- 8.2 nM as compared to 1.1 +/- 0.3 nM for alpha-bungarotoxin. However, at concentrations of thymopoietin of up to 1 microM, [3H]nicotine binding to high affinity sites was not inhibited. Thysplenin, a polypeptide with considerable homology to thymopoietin did not affect [125I]alpha-bungarotoxin binding. These results suggest that thymopoietin selectively interacts with the nicotinic alpha-bungarotoxin binding site labelled by [125I]alpha-bungarotoxin rather than the neuronal nicotinic receptor(s) labelled by [3H]nicotine. Autoradiographic studies revealed that 1 microM thymopoietin almost completely inhibited [125I]alpha-bungarotoxin binding in all brain regions. Computer-assisted image analysis of displacement curves was performed on various brain areas rich in alpha-bungarotoxin binding, such as the dorsal endopiriform nucleus, fields 1 and 2 of Ammon's horn, the polymorph cell layer of the dentate gyrus and cortical layers 4 and 5. Thymopoietin inhibited [125I]alpha-bungarotoxin binding with similar potency in all these regions, suggesting that it interacted at the same site in the different brain areas. The IC50 values averaged over the six regions were 24.6 +/- 2.8 nM for thymopoietin and 1.2 +/- 0.2 nM for alpha-bungarotoxin. These results show that thymopoietin specifically interacted with the alpha-bungarotoxin site with a similar potency in different brain regions. It is suggested that thymopoietin represents a selective ligand for alpha-bungarotoxin binding sites in brain.

Animals↗
PubMed1990

Neuronal nicotinic alpha-bungarotoxin receptors.

Recent evidence has indicated that the nicotinic acetylcholine receptor and the nicotinic alpha-bungarotoxin (alpha-BGT) site may be distinct in neuronal tissues. With regard to function, the former receptor appears to be involved in mediating synaptic events; however, the role of the nicotinic alpha-BGT site in nervous tissue is currently not known. Since the binding of alpha-BGT exhibits such high affinity and selectivity for a specific receptor, this may implicate an involvement of the toxin binding site in some aspect of neuronal activity with the receptor possibly mediating functions other than nicotinic cholinergic transmission. A further hypothesis to explain the nature of the toxin binding site may be that the natural ligand for the alpha-BGT site is one other than acetylcholine, with acetylcholine acting as a modulator of the site. Current studies in our laboratory are exploring these possibilities by determining whether specific peptides and/or polypeptides can interact at the nicotinic alpha-BGT site in nervous tissue. Studies using both in vivo and in vitro approaches suggest that thymopoietin may serve a role as a modulator of the nicotinic alpha-BGT site in neuronal tissues.

Adrenal Medulla↗
PubMed1990

Phorbol esters and d-tubocurarine up-regulate alpha-bungarotoxin sites in chromaffin cells in culture via distinct mechanisms.

Previous work had shown that nicotinic antagonists resulted in a marked up-regulation of alpha-bungarotoxin sites in chromaffin cells in culture. The present experiments were done to determine the intracellular mechanism(s) whereby nicotinic antagonists might mediate their effects on these receptors. Chromaffin cells were cultured for three days with various concentrations of 4 beta-phorbol 12-myristate 13-acetate, an agent which affects protein kinase C by mimicking the actions of diacylglycerol. The phorbol ester resulted in a dose-dependent increase in alpha-bungarotoxin binding which was maximal with 100 nM 4 beta-phorbol 12-myristate 13-acetate. This increase in binding appeared to be due to an increase in the maximal number of alpha-bungarotoxin sites. Time dependence studies showed that the effect of the phorbol was undetectable with incubations of 24 h or less and appeared to plateau by 72-96 h. A similar increase in toxin binding was also observed with 4 beta-phorbol 12,13-dibutyrate. On the other hand, an inactive analog of 4 beta-phorbol 12-myristate 13-acetate had no significant effect on binding. D-Sphingosine, an inhibitor of protein kinase C, was able to partially block the phorbol ester-induced increase in toxin binding while polymyxin B, another protein kinase C inhibitor, completely prevented the up-regulation of the alpha-bungarotoxin sites. Carbachol and nicotine prevented this enhancement of toxin binding in the presence of 4 beta-phorbol 12-myristate 13-acetate. Although the phorbol ester resulted in an increase in toxin binding, acetylcholine-evoked catecholamine secretion from chromaffin cells in culture was decreased, indicating a dissociation between the functional nicotinic acetylcholine receptor population and the alpha-bungarotoxin sites. To determine whether agents which affect protein kinase C can alter the up-regulation of alpha-bungarotoxin sites by d-tubocurarine, 4 beta-phorbol 12-myristate 13-acetate was added to the cells in combination with the nicotinic antagonist. The up-regulation of toxin binding sites induced by d-tubocurarine was additive with that induced by the phorbol and was not affected by polymyxin B. Thus, the results would suggest that there are at least two mechanisms by which alpha-bungarotoxin binding sites can be regulated. One is mediated via an interaction at nicotinic receptors, while the other occurs in response to phorbol esters and thus may be mediated by protein kinase C. Interestingly, although the molecular mechanisms resulting in alpha-bungarotoxin receptor up-regulation differ, both the d-tubocurarine- and the phorbol ester-induced increases were prevented by nicotinic receptor ligands.

Adrenal Medulla↗
PubMed1990

Thymopoietin, a thymic polypeptide, regulates nicotinic alpha-bungarotoxin sites in chromaffin cells in culture.

The identity of the neuronal nicotinic alpha-bungarotoxin (alpha-BGT) site, which appears to be distinct from the functional nicotinic receptor, is unclear. Recent work in our laboratory has shown that the thymus-derived polypeptide thymopoietin potently and specifically interacts at the nicotinic alpha-BGT site in brain. The present results show that thymopoietin also interferes with the binding of 125I-alpha-BGT to chromaffin cells in culture; a dose-dependent inhibition in binding was observed, with an IC50 of 10(-8) M. To assess the long term effect(s) of thymopoietin in nervous tissue, chromaffin cells were exposed to the polypeptide for varying periods of time. Incubation of the cells in culture with thymopoietin (10(-9) to 3 x 10(-7) M) for 2 to 7 days resulted in an approximate 3-fold increase in alpha-BGT binding. Saturation analysis indicated this was due to an increase in the Bmax. The thymopoietin-induced increase in binding could be reversed with nicotine: thus, the sites can be regulated by a nicotinic receptor ligand. Although thymopoietin potently interacted at the nicotinic alpha-BGT receptor, nicotinic receptor responsiveness was not affected after short or long term exposure to the peptide. Neither basal nor nicotinic receptor-stimulated tyrosine hydroxylase activity was altered by thymopoietin. As well, resting and acetylcholine-evoked noradrenaline release remained similar to control after exposure of the cells to the polypeptide. These results indicate that the thymic polypeptide thymopoietin specifically interacts with the nicotinic alpha-BGT receptor population and, furthermore, can regulate the toxin binding sites in chromaffin cells in culture.

Acetylcholine↗
PubMed1989

Thymopoietin, a thymic polypeptide, specifically interacts at neuronal nicotinic alpha-bungarotoxin receptors.

alpha-Bungarotoxin (alpha-BGT), a snake venom polypeptide, interacts potently and specifically with a nicotinic receptor population in neuronal tissue. However, the identity of this site is unclear, because, unlike at the neuromuscular junction and in electroplax, in nervous tissue the toxin does not block nicotinic cholinergic responses. Therefore, we sought endogenous compounds other than acetylcholine that could interact with the neuronal alpha-BGT site. In the present experiments, thymopoietin, a polypeptide isolated from the thymus, is shown to inhibit potently alpha-BGT binding to brain membranes in a dose-dependent manner (IC50 = 3.1 nM). This effect was not shared by a wide variety of other peptides, including thysplenin, a closely related polypeptide. Thymopoietin did not inhibit the binding of other radioligands known to interact with different populations of cholinergic receptors, such as [3H]nicotine and [3H]methylcarbachol, which bind to nicotinic receptors, or [3H]quinuclidinylbenzilate, which binds to muscarinic receptors. These results show that thymopoietin potently and specifically affects 125I-alpha-BGT binding to brain membranes and suggest that thymopoietin might be an endogenous ligand for alpha-BGT receptors in neuronal tissue.

Animals↗
PubMed1988

Regulation of alpha-bungarotoxin sites in chromaffin cells in culture by nicotinic receptor ligands, K+, and cAMP.

Previous work had shown that incubation with the nicotinic antagonist d-tubocurarine resulted in a marked increase in alpha-bungarotoxin (alpha-BGT) binding in adrenal medullary chromaffin cells in culture; the possible molecular mechanisms involved in up-regulating the alpha-BGT sites were investigated. To determine whether changes in the extracellular K+ concentration could influence the number of toxin binding sites, the chromaffin cells were incubated in the presence of 2-50 mM K+; this resulted in an increase in alpha-BGT binding similar to that observed with the nicotinic antagonist. This enhanced binding was maximal with 20 mM K+ and was not due simply to a generalized ion effect, inasmuch as incubation of the cells with a concentration of Na+ of equivalent osmolarity did not alter alpha-BGT binding. Carbachol and the agonist nicotine completely prevented the K+-induced increase in the binding sites. In contrast to the marked up-regulation of the nicotinic alpha-BGT sites by K+, this agent did not increase the acetylcholine-induced release of [3H]noradrenaline from chromaffin cells in culture, further supporting the contention that the nicotinic alpha-BGT site and the functional nicotinic receptor are distinct. The increases in toxin binding due to K+ and d-tubocurarine were partially additive, suggesting that d-tubocurarine and K+ may share a common pathway, but only to a small degree. The calcium channel agonist BAY K 8644 and antagonist D600 had no effect on alpha-BGT binding either alone or in the presence of K+ or d-tubocurarine. On the other hand, forskolin, an activator of adenylate cyclase, and dibutyryl cAMP, an analog of cAMP, partially prevented the K+ and the d-tubocurarine-induced increases in toxin binding. These results suggest an involvement of cAMP in both the nicotinic antagonist-induced and K+-induced up-regulation of the sites. The observation that several mechanisms exist for the fine regulation of the nicotinic alpha-BGT binding sites in adrenal chromaffin cells could imply that this nicotinic receptor population plays a role in this tissue.

3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethy↗